Advanced

EVOLUTION OF A beta 42 AND A beta 40 LEVELS AND A beta 42/A beta 40 RATIO IN PLASMA DURING PROGRESSION OF ALZHEIMER'S DISEASE: A MULTICENTER ASSESSMENT

Blennow, K.; De Meyer, G.; Hansson, Oskar LU ; Minthon, Lennart LU ; Wallin, A.; Zetterberg, H.; Lewczuk, P.; Vanderstichele, H.; Vanmechelen, E. and Kornhuber, J., et al. (2009) 1st Cconference Clinical Trials on Alzheimers Disease (CTAD) In Journal Of Nutrition Health & Aging 13(3). p.205-208
Abstract
Objective: To better understand the seemingly contradictory plasma beta-amyloid (A beta) results in Alzheimer's disease (AD) patients by using a newly developed plasma A beta assay, the INNO-BIA plasma A beta forms, in a multicenter study. Methods: A combined retrospective analysis of plasma A beta isoforms on mild cognitive impairment (MCI) from three large cross-sectional studies involving 643 samples from the participating German and Swedish centers. Results: Detection modules based on two different amino (N)-terminal specific A beta monoclonal antibodies demonstrated that A beta in plasma could be reliable quantified using a sandwich immunoassay technology with high precision, even for low A beta 42 plasma concentrations. A beta 40 and... (More)
Objective: To better understand the seemingly contradictory plasma beta-amyloid (A beta) results in Alzheimer's disease (AD) patients by using a newly developed plasma A beta assay, the INNO-BIA plasma A beta forms, in a multicenter study. Methods: A combined retrospective analysis of plasma A beta isoforms on mild cognitive impairment (MCI) from three large cross-sectional studies involving 643 samples from the participating German and Swedish centers. Results: Detection modules based on two different amino (N)-terminal specific A beta monoclonal antibodies demonstrated that A beta in plasma could be reliable quantified using a sandwich immunoassay technology with high precision, even for low A beta 42 plasma concentrations. A beta 40 and A beta 42 concentrations varied consistently with the ApoE genotype, while the A beta 42/A beta 40 ratio did not. Irrespective of the decrease of the A beta 42/A beta 40 ratio with age and MMSE, this parameter was strongly associated with AD, as defined in this study by elevated hyperphosphorylated (P-tau181P) levels in cerebrospinal fluid (CSF). Conclusion: A highly robust assay for repeatedly measuring A beta forms in plasma such as INNO-BIA plasma A beta forms might be a useful tool in a future risk assessment of AD. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Chapter in Book/Report/Conference proceeding
publication status
published
subject
in
Journal Of Nutrition Health & Aging
volume
13
issue
3
pages
205 - 208
publisher
Springer
conference name
1st Cconference Clinical Trials on Alzheimers Disease (CTAD)
external identifiers
  • wos:000265941200008
  • scopus:63249120625
ISSN
1279-7707
language
English
LU publication?
yes
id
74b45425-d9a9-4d8b-9a0f-b74f0113e8f2 (old id 1425988)
date added to LUP
2009-06-30 13:59:11
date last changed
2017-08-20 04:03:35
@inproceedings{74b45425-d9a9-4d8b-9a0f-b74f0113e8f2,
  abstract     = {Objective: To better understand the seemingly contradictory plasma beta-amyloid (A beta) results in Alzheimer's disease (AD) patients by using a newly developed plasma A beta assay, the INNO-BIA plasma A beta forms, in a multicenter study. Methods: A combined retrospective analysis of plasma A beta isoforms on mild cognitive impairment (MCI) from three large cross-sectional studies involving 643 samples from the participating German and Swedish centers. Results: Detection modules based on two different amino (N)-terminal specific A beta monoclonal antibodies demonstrated that A beta in plasma could be reliable quantified using a sandwich immunoassay technology with high precision, even for low A beta 42 plasma concentrations. A beta 40 and A beta 42 concentrations varied consistently with the ApoE genotype, while the A beta 42/A beta 40 ratio did not. Irrespective of the decrease of the A beta 42/A beta 40 ratio with age and MMSE, this parameter was strongly associated with AD, as defined in this study by elevated hyperphosphorylated (P-tau181P) levels in cerebrospinal fluid (CSF). Conclusion: A highly robust assay for repeatedly measuring A beta forms in plasma such as INNO-BIA plasma A beta forms might be a useful tool in a future risk assessment of AD.},
  author       = {Blennow, K. and De Meyer, G. and Hansson, Oskar and Minthon, Lennart and Wallin, A. and Zetterberg, H. and Lewczuk, P. and Vanderstichele, H. and Vanmechelen, E. and Kornhuber, J. and Wiltfang, J.},
  booktitle    = {Journal Of Nutrition Health & Aging},
  issn         = {1279-7707},
  language     = {eng},
  number       = {3},
  pages        = {205--208},
  publisher    = {Springer},
  title        = {EVOLUTION OF A beta 42 AND A beta 40 LEVELS AND A beta 42/A beta 40 RATIO IN PLASMA DURING PROGRESSION OF ALZHEIMER'S DISEASE: A MULTICENTER ASSESSMENT},
  volume       = {13},
  year         = {2009},
}